Treatment evolution in high-risk congenital diaphragmatic hernia: Ten years' experience with diaphragmatic agenesis

Kevin P. Lally, Pamela A. Lally, Krisa P. Van Meurs, Desmond J. Bohn, Carl F. Davis, Bradley Rodgers, Jatinder Bhatia, Golde Dudell

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

OBJECTIVE: The objective of this study was to evaluate the impact of newer therapies on the highest risk patients with congenital diaphragmatic hernia (CDH), those with agenesis of the diaphragm. SUMMARY BACKGROUND DATA: CDH remains a significant cause of neonatal mortality. Many novel therapeutic interventions have been used in these infants. Those children with large defects or agenesis of the diaphragm have the highest mortality and morbidity. METHODS: Twenty centers from 5 countries collected data prospectively on all liveborn infants with CDH over a 10-year period. The treatment and outcomes in these patients were examined. Patients were followed until death or hospital discharge. RESULTS: A total of 1569 patients with CDH were seen between January 1995 and December 2004 in 20 centers. A total of 218 patients (14%) had diaphragmatic agenesis and underwent repair. The overall survival for all patients was 68%, while survival was 54% in patients with agenesis. When patients with diaphragmatic agenesis from the first 2 years were compared with similar patients from the last 2 years, there was significantly less use of ECMO (75% vs. 52%) and an increased use of inhaled nitric oxide (iNO) (30% vs. 80%). There was a trend toward improved survival in patients with agenesis from 47% in the first 2 years to 59% in the last 2 years. The survivors with diaphragmatic agenesis had prolonged hospital stays compared with patients without agenesis (median, 68 vs. 30 days). For the last 2 years of the study, 36% of the patients with agenesis were discharged on tube feedings and 22% on oxygen therapy. CONCLUSIONS: There has been a change in the management of infants with CDH with less frequent use of ECMO and a greater use of iNO in high-risk patients with a potential improvement in survival. However, the mortality, hospital length of stay, and morbidity in agenesis patients remain significant.

Original languageEnglish (US)
Pages (from-to)505-511
Number of pages7
JournalAnnals of Surgery
Volume244
Issue number4
DOIs
StatePublished - Oct 1 2006

Fingerprint

Therapeutics
Length of Stay
Survival
Diaphragm
Congenital Diaphragmatic Hernias
Nitric Oxide
Morbidity
Mortality
Infant Mortality
Enteral Nutrition
Survivors
Oxygen

ASJC Scopus subject areas

  • Surgery

Cite this

Lally, K. P., Lally, P. A., Van Meurs, K. P., Bohn, D. J., Davis, C. F., Rodgers, B., ... Dudell, G. (2006). Treatment evolution in high-risk congenital diaphragmatic hernia: Ten years' experience with diaphragmatic agenesis. Annals of Surgery, 244(4), 505-511. https://doi.org/10.1097/01.sla.0000239027.61651.fa

Treatment evolution in high-risk congenital diaphragmatic hernia : Ten years' experience with diaphragmatic agenesis. / Lally, Kevin P.; Lally, Pamela A.; Van Meurs, Krisa P.; Bohn, Desmond J.; Davis, Carl F.; Rodgers, Bradley; Bhatia, Jatinder; Dudell, Golde.

In: Annals of Surgery, Vol. 244, No. 4, 01.10.2006, p. 505-511.

Research output: Contribution to journalArticle

Lally, Kevin P. ; Lally, Pamela A. ; Van Meurs, Krisa P. ; Bohn, Desmond J. ; Davis, Carl F. ; Rodgers, Bradley ; Bhatia, Jatinder ; Dudell, Golde. / Treatment evolution in high-risk congenital diaphragmatic hernia : Ten years' experience with diaphragmatic agenesis. In: Annals of Surgery. 2006 ; Vol. 244, No. 4. pp. 505-511.
@article{8ad0683eccdd40af9583a5cf918cbe0b,
title = "Treatment evolution in high-risk congenital diaphragmatic hernia: Ten years' experience with diaphragmatic agenesis",
abstract = "OBJECTIVE: The objective of this study was to evaluate the impact of newer therapies on the highest risk patients with congenital diaphragmatic hernia (CDH), those with agenesis of the diaphragm. SUMMARY BACKGROUND DATA: CDH remains a significant cause of neonatal mortality. Many novel therapeutic interventions have been used in these infants. Those children with large defects or agenesis of the diaphragm have the highest mortality and morbidity. METHODS: Twenty centers from 5 countries collected data prospectively on all liveborn infants with CDH over a 10-year period. The treatment and outcomes in these patients were examined. Patients were followed until death or hospital discharge. RESULTS: A total of 1569 patients with CDH were seen between January 1995 and December 2004 in 20 centers. A total of 218 patients (14{\%}) had diaphragmatic agenesis and underwent repair. The overall survival for all patients was 68{\%}, while survival was 54{\%} in patients with agenesis. When patients with diaphragmatic agenesis from the first 2 years were compared with similar patients from the last 2 years, there was significantly less use of ECMO (75{\%} vs. 52{\%}) and an increased use of inhaled nitric oxide (iNO) (30{\%} vs. 80{\%}). There was a trend toward improved survival in patients with agenesis from 47{\%} in the first 2 years to 59{\%} in the last 2 years. The survivors with diaphragmatic agenesis had prolonged hospital stays compared with patients without agenesis (median, 68 vs. 30 days). For the last 2 years of the study, 36{\%} of the patients with agenesis were discharged on tube feedings and 22{\%} on oxygen therapy. CONCLUSIONS: There has been a change in the management of infants with CDH with less frequent use of ECMO and a greater use of iNO in high-risk patients with a potential improvement in survival. However, the mortality, hospital length of stay, and morbidity in agenesis patients remain significant.",
author = "Lally, {Kevin P.} and Lally, {Pamela A.} and {Van Meurs}, {Krisa P.} and Bohn, {Desmond J.} and Davis, {Carl F.} and Bradley Rodgers and Jatinder Bhatia and Golde Dudell",
year = "2006",
month = "10",
day = "1",
doi = "10.1097/01.sla.0000239027.61651.fa",
language = "English (US)",
volume = "244",
pages = "505--511",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Treatment evolution in high-risk congenital diaphragmatic hernia

T2 - Ten years' experience with diaphragmatic agenesis

AU - Lally, Kevin P.

AU - Lally, Pamela A.

AU - Van Meurs, Krisa P.

AU - Bohn, Desmond J.

AU - Davis, Carl F.

AU - Rodgers, Bradley

AU - Bhatia, Jatinder

AU - Dudell, Golde

PY - 2006/10/1

Y1 - 2006/10/1

N2 - OBJECTIVE: The objective of this study was to evaluate the impact of newer therapies on the highest risk patients with congenital diaphragmatic hernia (CDH), those with agenesis of the diaphragm. SUMMARY BACKGROUND DATA: CDH remains a significant cause of neonatal mortality. Many novel therapeutic interventions have been used in these infants. Those children with large defects or agenesis of the diaphragm have the highest mortality and morbidity. METHODS: Twenty centers from 5 countries collected data prospectively on all liveborn infants with CDH over a 10-year period. The treatment and outcomes in these patients were examined. Patients were followed until death or hospital discharge. RESULTS: A total of 1569 patients with CDH were seen between January 1995 and December 2004 in 20 centers. A total of 218 patients (14%) had diaphragmatic agenesis and underwent repair. The overall survival for all patients was 68%, while survival was 54% in patients with agenesis. When patients with diaphragmatic agenesis from the first 2 years were compared with similar patients from the last 2 years, there was significantly less use of ECMO (75% vs. 52%) and an increased use of inhaled nitric oxide (iNO) (30% vs. 80%). There was a trend toward improved survival in patients with agenesis from 47% in the first 2 years to 59% in the last 2 years. The survivors with diaphragmatic agenesis had prolonged hospital stays compared with patients without agenesis (median, 68 vs. 30 days). For the last 2 years of the study, 36% of the patients with agenesis were discharged on tube feedings and 22% on oxygen therapy. CONCLUSIONS: There has been a change in the management of infants with CDH with less frequent use of ECMO and a greater use of iNO in high-risk patients with a potential improvement in survival. However, the mortality, hospital length of stay, and morbidity in agenesis patients remain significant.

AB - OBJECTIVE: The objective of this study was to evaluate the impact of newer therapies on the highest risk patients with congenital diaphragmatic hernia (CDH), those with agenesis of the diaphragm. SUMMARY BACKGROUND DATA: CDH remains a significant cause of neonatal mortality. Many novel therapeutic interventions have been used in these infants. Those children with large defects or agenesis of the diaphragm have the highest mortality and morbidity. METHODS: Twenty centers from 5 countries collected data prospectively on all liveborn infants with CDH over a 10-year period. The treatment and outcomes in these patients were examined. Patients were followed until death or hospital discharge. RESULTS: A total of 1569 patients with CDH were seen between January 1995 and December 2004 in 20 centers. A total of 218 patients (14%) had diaphragmatic agenesis and underwent repair. The overall survival for all patients was 68%, while survival was 54% in patients with agenesis. When patients with diaphragmatic agenesis from the first 2 years were compared with similar patients from the last 2 years, there was significantly less use of ECMO (75% vs. 52%) and an increased use of inhaled nitric oxide (iNO) (30% vs. 80%). There was a trend toward improved survival in patients with agenesis from 47% in the first 2 years to 59% in the last 2 years. The survivors with diaphragmatic agenesis had prolonged hospital stays compared with patients without agenesis (median, 68 vs. 30 days). For the last 2 years of the study, 36% of the patients with agenesis were discharged on tube feedings and 22% on oxygen therapy. CONCLUSIONS: There has been a change in the management of infants with CDH with less frequent use of ECMO and a greater use of iNO in high-risk patients with a potential improvement in survival. However, the mortality, hospital length of stay, and morbidity in agenesis patients remain significant.

UR - http://www.scopus.com/inward/record.url?scp=33748936547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748936547&partnerID=8YFLogxK

U2 - 10.1097/01.sla.0000239027.61651.fa

DO - 10.1097/01.sla.0000239027.61651.fa

M3 - Article

C2 - 16998359

AN - SCOPUS:33748936547

VL - 244

SP - 505

EP - 511

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 4

ER -